

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥（煙台）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

Voluntary Announcement Resolution on Repurchase of A Shares of the Company

This announcement is made voluntarily by RemeGen Co., Ltd. (the “**Company**”) to the shareholders of the Company (the “**Shareholders**”) and potential investors.

The Company convened the thirty-second meeting of the second session of the Board of Directors (the “**Board**”) on December 15, 2025, and considered and approved the Resolution on the Plan for Repurchase of A Shares of the Company (the “**Relevant Resolution**”). In accordance with the relevant rules on Repurchase of Shares by Listed Companies (《上市公司股份回購規則》) and the Articles of Association of the Company, the plan for the Repurchase of A Shares may be implemented upon approval by the Board with the attendance of more than two-thirds of the directors, and is not required to be submitted to the shareholders’ general meeting of the Company for approval.

Pursuant to the Relevant Resolution, the Company proposes to repurchase part of its A shares (the “**Repurchase of A Shares**”) by way of centralised price bidding for the purpose of implementing an employee equity incentive scheme in the future. If the Company fails to fully utilize the repurchased shares within 3 years after the announcement of the share repurchase implementation results and share changes, any unused repurchased shares will be cancelled. If national policies are adjusted, the Repurchase of A Shares will be implemented in accordance with the adjusted policies. The sources of funds for the Repurchase of A Shares shall be the Company’s own funds and/or self-raised funds.

The total amount for the Repurchase of A Shares shall not be less than RMB20 million (inclusive) and not more than RMB40 million (inclusive). The price for the Repurchase of A Shares shall not be more than RMB95 per share (inclusive) and this price does not exceed 150% of the Company’s average stock trading price over the 30 trading days preceding the Board’s approval of the Relevant Resolution. Based on the maximum repurchase price, the estimated number of A Shares to be repurchased is between 210,500 and 421,100 shares. The period for the Repurchase of A Shares shall be no more than 12 months from the date of the approval of the plan for the Repurchase of A Shares by the Board. If, during the implementation period, the trading of the Company’s shares is suspended for 10 consecutive trading days or more due to the planning of a significant matter, the repurchase period shall be extended accordingly upon the resumption of trading, and such extension shall be disclosed in a timely manner.

As of December 15, 2025, the Company's controlling shareholders, actual controllers and their concerted parties, other directors, senior management, and shareholders holding more than 5% of the shares currently have no plans to reduce their holdings of the Company's A Shares within the next 3 months or the next 6 months. If relevant personnel intend to implement A Share reduction plans in the future, the Company will promptly fulfill information disclosure obligations in accordance with relevant regulations.

For details of the plan for the Repurchase of A Shares, please refer to the overseas regulatory announcement of the Company titled "*Plan for the Repurchase of A Shares by Centralised Price Bidding*" dated December 16, 2025.

The Company believes that the Repurchase of A Shares will help establish a long-term incentive mechanism, align the interests of Shareholders, the Company and its employees, and enhance investor confidence, which is in the interests of the Company and the Shareholders as a whole.

Shareholders and investors are advised to pay attention that the repurchase of shares will be subject to market conditions. There is no guarantee as to the timing, volume or price of the repurchase of shares, or whether the Company will repurchase any shares. Therefore, Shareholders and investors are advised to exercise caution when dealing in shares.

By Order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive director

Yantai, the People's Republic of China,
December 15, 2025

As at the date of this announcement, the Board of the Company comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Lin Jian and Mr. Wen Qingkai as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive directors.

* For identification purposes only